Change - Announcement of Cessation::Cessation of an Executive Director

Issuer & Securities

Issuer/ Manager
HYPHENS PHARMA INTERNATIONAL LIMITED
Securities
HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Cessation
Date &Time of Broadcast
10-Apr-2023 07:49:16
Status
New
Announcement Sub Title
Cessation of an Executive Director
Announcement Reference
SG230410OTHRTRVP
Submitted By (Co./ Ind. Name)
Lim See Wah
Designation
Executive Chairman and CEO
Description (Please provide a detailed description of the event in the box below)
Cessation of Mr Tan Chwee Choon as an Executive Director of the Company.

This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: +65 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

Additional Details

Name Of Person
Tan Chwee Choon
Age
66
Is effective date of cessation known?
Yes
If yes, please provide the date
26/04/2023
Detailed Reason (s) for cessation
Mr Tan Chwee Choon ("Mr Tan") will be retiring as Director of the Company pursuant to Regulation 97 of the Constitution of the Company. Mr Tan indicated that he would not seek for re-election as Director of the Company and would retire at the conclusion of the Annual General Meeting of the Company to be held on 26 April 2023.

Further, the Sponsor, after having interviewed Mr Tan, is satisfied that, other than as disclosed in this announcement, there are no material reasons for the retirement of Mr Tan as an Executive Director of the Company.

The Company expresses its gratitude to Mr Tan for his valuable contributions during his tenure of service.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
No
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
No
Any other relevant information to be provided to shareholders of the listed issuer?
No
Date of Appointment to current position
12/12/2017
Does the AC have a minimum of 3 members (taking into account this cessation)?
Yes
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
4
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
1
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Director
Role and responsibilities
Responsible for managing the Indochina operations.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Nil
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Mr Tan Chwee Choon has a direct interest of 38,045,560 ordinary shares (12.32%) in the Company.
Other Directorships
Past (for the last 5 years)
DAC Pharmalab Pte Ltd, Singapore
Ocean Healthcare (M) Sdn. Bhd., Malaysia
Present
Within the Group:
Hyphens Pharma Pte. Ltd., Singapore
Ocean Health Pte. Ltd., Singapore
Pan-Malayan Pharmaceuticals Pte Ltd, Singapore
Hyphens Pharma Philippines, Inc., Philippines
Subsequent to this announcement, Mr Tan will also step down as a director of the above-mentioned Group's subsidiaries on 26 April 2023.

Outside the Group:
LTT Investments Pte. Ltd., Singapore